



My
News


Today's
Paper

QLD

World

Sport

Business

Opinion

Education

Health

Lifestyle

Entertainment

Puzzles




Business Stockhead

The dementia challenge: Which ASX



The search for a dementia breakthrough is gathering pace in Australia and around the world. Pic: Getty Images


Dementia is one of the leading cause of death in Australia while ranking among major causes of disability and dependency in older people



dependency among older people.

That research effort includes Australia, which is marking Dementia Action Week. To coincide with the week, seven Australian startups were announced as recipients of a combined \$15.6 million in funding to accelerate the development of new treatments, diagnostics and technologies for dementia and cognitive decline.

The funding is the second round for the Australian Government's Medical Research Future Fund (MRFF) CUREator+ Dementia & Cognitive Decline



Cummings.

a major area of unmet need, with significant investment around the world
My News Feed [Read More >](#)
focused on tackling the disease.



Leaders & Companies



SA News



Business

Cogstate at forefront of Alzheimer's

clinical trials
Bobbin has had
directors ousted at
iconic Aussie company
Cogstate (ASX:CGS)

Mayfair Hotel to be
transformed after
\$75m sale

Digital air traffic
control towers not fit
for WFH, says
Airservices boss

is working with several big pharma companies as they
work to develop potential treatments for Alzheimer's disease, which is the
most common cause of dementia, including US-based Eli Lilly and Japanese
drug developer, Eisai.

and data quality for Lilly's successful pivotal phase III trial of donanemab
Good Morning George Recommended based on what you've read
(brand name Kisunla).



QLD News



Gympie



Gympie

Donanemab is a monoclonal antibody administered by intravenous (IV)
infusion and designed to target and remove amyloid plaques from the brain.

**Man, 33, dies after
horror e-bike crash in
Brisbane**

**Thousands of
complaints drive major
Gympie council
overhaul**

**Council's double pike
in battle royale over
shed**

The phase III trial assessed whether removing the plaques could slow
cognitive and functional decline in people with early Alzheimer's disease.

Eisai is the developer of lecanemab (Leqembi), another disease-modifying
Alzheimer's treatment which targets amyloid in the brain, and was approved
by the FDA in 2023.

CGS manages cognitive endpoints on behalf of pharmaceutical companies,
Trending now [Read More](#)
using a combination of technology and human services to ensure the quality
of data collected at clinical trial sites for Alzheimer's and other

**Autistic generative disc
from Earl Spencer's
Diana memoir**



"We're essentially a one-part technology, one-part services business,"

O'Connor said.

Unacceptable. PM

lashes OpenAI Medicare

back, three more sites
We're managing, on behalf of the pharmaceutical companies, all
compromised
cognitive endpoints, to ensure the accuracy and quality of the data that's
being collected."

QLD News

BOM website works for
He said that work includes
nine-hours on eve of
storm season



Let Them Be Kids

'Ultimate sycophant':
Harry hails Aussie social
media ban, warns of AI
threat



- Training staff at clinical trial sites (research hospitals)
- Monitoring (auditing) of that data to ensure quality
- Delivery of telehealth-style assessments by Cogstate's 400-plus
- Consulting neuropsychologists and human

Q&A

Dad's life-changing
holiday park injury
sparks \$20m lawsuit



'What?': Australian
Council's 39k fines rakes
in \$8m



QLD Politics

O'Connor said all these services and technology were designed to identify

\$32bn data centre to
potential errors in the data
consume more electricity
than biggest coal station



Puzzles

CGS is now managing cognitive endpoints and ensuring data qual

Boy George gained fame
in 1980s as lead singer of what band?



Lilly and Eisai as they investigate whether their approved early Al
treatments can be used even earlier.

Celebrity

O'Connor said the companies were moving into treating "pre-symptomatic" or
"pre-clinical" Alzheimer's disease, where people may have amyloid
their brains but do not yet have the memory impairment associated
dementia.

Shock lives of 40yo
Hanson brothers now



"It's sort of akin to treating cholesterol to prevent heart disease," O'Connor
said, referring to the prospect of treating amyloid accumulation before
significant cognitive symptoms develop.

"These plaques can occur up to 20 years before symptoms arrive.

"The hypothesis is that if removed through treatment before symptoms, can
the symptoms be stopped from ever occurring."

He said the shift toward treating Alzheimer's earlier was also being enabled
by advances in blood-based biomarkers.

Stockhead

In July 2026, Australia's Therapeutic Goods Administration (TGA) approved a
blood test that can help identify amyloid pathology associated with
Alzheimer's disease.

Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) test was developed in
collaboration with Eli Lilly and was also cleared in August by the FDA.

"Eli Lilly's and Eisai's phase III trials are expected to conclude in 2027 and if
they work Alzheimer's has changed forever because we now start treating
people at the pre-symptomatic stage," O'Connor said.

CGS also has a Cognigram Digital Cognitive Assessment System, used by
physicians to measure cognitive function and detect changes over time.

It assesses areas including processing speed, attention, visual learning,
working memory, visual motor function and executive function.

The test can be used to assess cognition at a single point in time or track cognitive change through periodic assessments.

"There is a potential future where a simple blood test can identify the formation of plaques in the brain," O'Connor said.

"Cogstate digital assessments can then identify any functional impairment which will provide insight into the potential rate of decline.

"Then, through drugs approved for use in this earlier stage of disease, we can remove plaques before the horrendous memory impairment takes hold. It is super exciting."

Countdown to Actinogen's phase III Alzheimer's trial readout

[Actinogen Medical \(ASX:ACW\)](#) is the only ASX-listed healthcare company with an advanced program focused on Alzheimer's disease.

ACW's lead candidate Xanamem is in a phase 2b/3 trial dubbed XanaMIA, with topline results expected in November.

Xanamem is described by the company as the "first and only potent oral inhibitor of 11 β -HSD1", an enzyme involved in regulating cortisol in brain regions linked to memory and mood.

The oral drug candidate is designed to reduce excess cortisol production in the brain while preserving normal cortisol levels elsewhere in the body, with the aim of slowing cognitive decline.

"As national conversations around brain health take centre stage for Dementia Action Week, our team is staying sharply focused on our November trial readout," ACW chief financial officer Will Souter told Stockhead.

"We are rapidly approaching a pivotal moment that we hope will deliver a meaningful new treatment option for patients and their families."

"Dementia Action Week is a timely reminder of why we do what we do every day at Actinogen.

With trial sites fully enrolled and our upcoming November results on track, we are working hard to advance Xanamem toward becoming a potential breakthrough in Alzheimer's care."

Alterity eyes broader dementia potential for lead drug

[Alterity Therapeutics \(ASX:ATH\)](#) is developing its lead asset ATH434 for multiple system atrophy (MSA), a rare and aggressive Parkinsonian disorder.

The neurodegenerative disease, which affects up to 50,000 patients in the US, is characterised by the build-up of excess iron and aggregation of a protein called alpha-synuclein in the central nervous system (CNS).

ATH said the underlying biology is relevant across a broader group of neurodegenerative diseases.

Alpha-synuclein is a shared hallmark of MSA, Parkinson's disease, and dementia with Lewy bodies, one of the most common forms of dementia after Alzheimer's disease. Alzheimer's itself is driven by different proteins, amyloid-beta and tau.

The company describes ATH434 as an "iron chaperone", an orally administered small molecule designed to redistribute excess reactive iron within brain cells.

"ATH434 targets excess reactive iron in the brain, a key driver of alpha-synuclein misfolding," CEO Dr David Stamler told Stockhead.

"Right now our focus is on Multiple System Atrophy, a rapidly progressing disease with no approved therapy.

"The alpha-synuclein protein misfolds in a number of other neurodegenerative diseases, including dementia with Lewy bodies and in Parkinson's disease, where many patients develop dementia."

In preclinical models of MSA and Parkinson's disease, ATH434 reduced alpha-synuclein aggregation, preserved neurons, and improved motor function.

ATH is preparing for a phase III trial of ATH434 in MSA after reaching agreement with the US Food and Drug Administration (FDA) at an End-of-Phase 2 meeting on key elements of the study design, including the dose and primary endpoint. ATH434 has FDA Fast Track designation and orphan drug designation in the US and EU.

While MSA is ATH's immediate focus, the company sees potential for ATH434 to be explored in other neurodegenerative diseases, including dementia with Lewy Bodies.

"The biology we are targeting is shared across these conditions, which is why the mechanism is relevant well beyond MSA," Stamler said.

The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

At Stockhead, we tell it like it is. While Alterity Therapeutics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [The dementia challenge: Which ASX stocks are chasing a breakthrough?](#)

Business Newsletter

Hi George, get trusted business news delivered direct to your inbox.

[Sign up](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription packages	About us	Help & support	Herald Sun	Buy Search Sell Classifieds	 
Group/Corporate subscriptions	Meet the team	FAQs	The Daily Telegraph	Find Your Local	
The Courier Mail app	Job opportunities	Standards of practice	The Advertiser	Foxsports	
Today's Paper	Code of conduct	Letter to the Editor	news.com.au	Foxtel	
Newsletters	Subscription FAQs	Licensing & Reprints	The Australian	Hipages	
	Subscription terms	Advertise with us	The Mercury	Kayo	
	Financial Hardship Policy		Geelong Advertiser	My Tributes	
			The Cairns Post	odds.com.au	
			Gold Coast Bulletin	Punters	
			Townsville Bulletin	racenet.com.au	
			The Chronicle	realestate.com.au	
			NT News	News24 Australia	
			The Weekly Times	Coupons	
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.